MOLECULAR MECHANISMS UNDERLYING HEPARIN-INDUCED LEUKOCYTOSIS

肝素诱导白细胞增多的分子机制

• 批准号: 8361868
• 负责人: Lianchun Wang
• 金额: $ 0.18万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-02-01 至 2012-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361868
• 关键词: Clinical; Funding; Grant; Heparin; Leukocyte Trafficking; Leukocytosis; Molecular; National Center for Research Resources; Patients; Pharmaceutical Preparations; Principal Investigator; Research; Research Infrastructure; Resources; Source; United States National Institutes of Health; cost; dosage

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. It has been manifested clinically for many years that heparin induces leukocytosis in patients after receiving the drug, suggesting that heparin at clinical dosage transiently modulates leukocyte trafficking in patients. However, to date, it still remains unknown how heparin treatment leads to the leukocytosis in patients.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 多年来的临床研究表明，肝素在给药后会引起患者的白细胞增多，提示临床剂量的肝素对患者的白细胞转运有短暂的调节作用。然而，到目前为止，肝素治疗是如何导致患者白细胞增多的仍不清楚。